Archemix Corporation

The University of Chicago

Iveric Bio, Inc.

Thomas Greene McCauley

Charles Wilson

David Epstein

Markus Kurz

James Rottman

Jeffrey C Kurz

Claude Benedict

Dilara McCauley

John Louis Diener

Dilara Grate

Martin Stanton

Kristin Thompson

Sara Chesworth Keene

Anna J Zoltoski

Dieter M Gruen

Alan R Krauss

Dan Zhou

Nobuko Hamaguchi

Tony Keefe

Kristin A Marshall

Errol Desouza

Jeffrey Kurz

Dilârâ McCauley

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Aptamer therapeutics useful in the treatment of complement-related disorders

Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.

Aptamers comprising CPG motifs

Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics

Methods for engineering a nucleic acid sensor molecule are provided. Biosensors comprise a plurality of nucleic acid sensor molecules labeled with a first signaling moiety and a second signaling moiety. The nucleic acid sensor molecules recognizes target molecules which do not naturally bind to DNA. Binding of a target molecule to the sensor molecules triggers a change in the proximity of the signaling moieties which leads to a change in the optical properties of the nucleic acid sensor molecules on the biosensor. Reagents and systems for performing the method are also provided. The method is useful in diagnostic applications and drug optimization.

Nucleic acid sensor molecules and methods of using same

A method for controlling the crystallite size and growth rate of plasma-deposited diamond films. A plasma is established at a pressure in excess of about 55 Torr with controlled concentrations of hydrogen up to about 98% by volume, of unsubstituted hydrocarbons up to about 3% by volume and an inert gas of one or more of the noble gases and nitrogen up to about 98% by volume. The volume ratio of inert gas to hydrogen is preferably maintained at greater than about 4, to deposit a diamond film on a suitable substrate. The diamond film is deposited with a predetermined crystallite size and at a predetermined growth rate.

Tailoring nanocrystalline diamond film properties

Growing community of inventors

Cambridge, MA, United States of America

Thomas Greene McCauley